



# Title: Risk-Reducing Mastectomy

Related Policies:	-	Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary
		Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
	-	Genetic Cancer Susceptibility Panels Using Next Generation
		Sequencing
	-	Breast Reconstructive Surgery After Mastectomy

Professional / Institutional	
Original Effective Date: June 7, 2004 / October 28, 2011	
Latest Review Date: October 28, 2025	
Current Effective Date: September 22, 2022	

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact <u>Blue Cross and Blue Shield of Kansas Customer Service</u>.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

Populations	Interventions	Comparators	Outcomes
Individuals:	Interventions of	Comparators of	Relevant outcomes include:
With high risk of breast	interest are:	interest are:	Overall survival
cancer or extensive	<ul> <li>Risk-reducing</li> </ul>	<ul> <li>Active surveillance</li> </ul>	Disease-specific survival
mammographic	mastectomy	<ul> <li>Standard of care</li> </ul>	Functional outcomes
abnormalities precluding			Treatment-related
excision or biopsy			morbidity
Individuals:	Interventions of	Comparators of	Relevant outcomes include:
With unilateral breast	interest are:	interest are:	Overall survival
cancer but are not	<ul> <li>Contralateral</li> </ul>	<ul> <li>Active surveillance</li> </ul>	Disease-specific survival
otherwise at high risk	risk-reducing	<ul> <li>Standard of care</li> </ul>	Functional outcomes
	mastectomy		Treatment-related
			morbidity

#### **DESCRIPTION**

Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to reduce the risk of breast cancer occurrence.

### **OBJECTIVE**

The objective of this evidence review is to determine whether risk-reducing mastectomy and/or contralateral risk-reducing mastectomy improves the net health outcome in individuals at risk for breast cancer.

### **BACKGROUND**

Risk-reducing mastectomy may be considered in individuals thought to be at high-risk of developing breast cancer, either due to family history, presence of genetic variants (eg, *BRCA1*, *BRCA2*, *PALB2*), having received radiotherapy to the chest, or the presence of lesions associated with an increased cancer risk such as lobular carcinoma in situ. Therefore, bilateral risk-reducing mastectomy may be performed to eliminate the risk of cancer arising elsewhere; chemoprevention and close surveillance are alternative risk-reduction strategies. Risk-reducing mastectomies are typically bilateral but can also describe a unilateral mastectomy in a patient who has previously undergone or is currently undergoing a mastectomy in the opposite breast for invasive cancer (ie, contralateral risk-reducing mastectomy). Use of contralateral risk-reducing mastectomy has increased in the U.S. An analysis of data from the National Cancer Database found that the rate of contralateral risk-reducing mastectomy in individuals diagnosed with unilateral stage I, II, or III breast cancer increased from approximately 4% in 1998 to 9.4% in 2002.<sup>1,</sup> Another analysis of data from the National Cancer Database (N=765,487) found that individuals with unilateral stage I breast cancer commonly underwent contralateral risk-reducing mastectomy, with an increase between 2006 (6%) and 2016 (9%).<sup>2,</sup>

The appropriateness of a risk-reducing mastectomy is a complicated risk-benefit analysis that requires estimates of a patient's risk of breast cancer, typically based on the patient's family history of breast cancer and other factors. Several models are available to assess risk of breast cancer.<sup>3,</sup> The specific risk factors included in the models vary, but all incorporate characteristics related to age, reproductive history, and family history. Race should also be considered when assessing risk. According to an analysis of the Surveillance, Epidemiology, and End Results program (SEER) from 2000 to 2015 (N=459,916), the risk of invasive contralateral breast cancer was higher in Black (hazard ratio, 1.44; 95% confidence interval, 1.35 to 1.54) and Hispanic individuals (hazard ratio, 1.11; 95% confidence interval, 1.02 to 1.20) compared to White individuals.<sup>4,</sup> In addition to the patient's risk assessment, the choice of a risk-reducing mastectomy is based on patient tolerance for risk, consideration of changes to appearance and need for additional cosmetic surgery, and the risk-reduction offered by mastectomy versus other options.

# **REGULATORY STATUS**

Mastectomy is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

### **POLICY**

- A. Unilateral or bilateral risk-reducing mastectomy may be considered **medically necessary** in individuals at high risk of breast cancer with one of the following:
  - 1. A known BRCA1 or BRCA2 variant, **OR**
  - 2. Received radiotherapy to the chest between the ages of 10 and 30 years, **OR**
  - 3. Presence of lobular carcinoma in situ, **OR**
  - 4. Lifetime risk of developing breast cancer of 20% or greater as identified by models that are largely defined by family history, **OR**
  - 5. Another gene variant associated with increased risk (e.g., *TP53* [Li-Fraumeni syndrome], PTEN [Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome], *CDH1*, *STK11*, and *PALB2*).
- B. Risk-reducing mastectomy is considered **experimental / investigational** for all other indications, including but not limited to contralateral risk-reducing mastectomy in individuals with breast cancer who do not meet high risk criteria.

### **POLICY GUIDELINES**

- A. It is strongly recommended that all candidates for risk-reducing mastectomy undergo counseling regarding cancer risks from a health professional skilled in assessing cancer risk other than the operating surgeon and discussion of the various treatment options, including increased surveillance or chemoprevention with tamoxifen or raloxifene.
- B. There is no standardized method for determining an individual's risk of breast cancer that incorporates all possible risk factors. There are validated risk prediction models, but they are based primarily on family history.
- C. A number of other factors may increase the risk of breast cancer but do not by themselves indicate high risk (generally considered to be a lifetime risk of ≥20%). It is possible that combinations of these factors may be indicative of high risk, but it is not possible to give quantitative estimates of risk. As a result, it may be necessary to individualize the estimate of risk taking into account numerous risk factors. A number of risk factors, not individually indicating high risk, are included in the National Cancer Institute Breast Cancer Risk Assessment Tool, also called the Gail model.
- D. Another breast cancer risk assessment tool, used in the Women Informed to Screen Depending on Measures of Risk trial, is the Breast Cancer Surveillance Consortium (BCSC) Risk Calculator (https://tools.bcsc-scc.org/bc5yearrisk/calculator.htm). The following information is used in that assessment tool:
  - History of breast cancer, ductal carcinoma in situ, breast augmentation, or mastectomy
  - 2. Age
  - 3. Race/ethnicity
  - 4. Number of first-degree relatives (mother, sister, or daughter) diagnosed with breast cancer
  - 5. Prior breast biopsies (positive or negative)
  - 6. Breast Imaging Reporting and Data System (BI-RADS) breast density (radiologic assessment of breast tissue density by radiologists who interpret mammograms).

Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

#### **RATIONALE**

This evidence review was created using searches of the PubMed database. The most recent literature update was performed through July 18, 2025.

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function-including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

#### RISK-REDUCING MASTECTOMY

# **Clinical Context and Therapy Purpose**

The purpose of a risk-reducing mastectomy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with a high-risk of breast cancer or extensive mammographic abnormalities precluding excision or biopsy.

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals at high-risk of breast cancer or with extensive mammographic abnormalities precluding excision or biopsy. High-risk is generally considered to be a lifetime risk of 20% or greater. The following list of factors may indicate a high-risk of breast cancer:

- lobular carcinoma in situ which is a precursor to invasive lobular cancer (up to 35% may be bilateral);
- a known BRCA1 or BRCA2 variant;

- another gene variant associated with high-risk, eg, TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), CDH1, STK11, and PALB2;
- received radiotherapy to the chest between 10 and 30 years of age.

### **Interventions**

The therapy being considered is a risk-reducing mastectomy.

Risk-reducing mastectomy is defined as the removal of the breast in the absence of malignant disease to reduce the risk of breast cancer occurrence.

# **Comparators**

The following practice is currently being used to treat individuals at high-risk of breast cancer or with extensive mammographic abnormalities precluding excision or biopsy: guideline directed active surveillance or use of chemoprevention.

### **Outcomes**

The general outcomes of interest are overall survival (OS), disease-specific survival, functional outcomes, and treatment-related morbidity.

# **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought;
- Studies with duplicative or overlapping populations were excluded.

### **REVIEW OF EVIDENCE**

### **Systematic Reviews**

Several recent systematic reviews have evaluated the impact of a risk-reducing mastectomy on health outcomes in women with *BRCA* variants. Li et al (2016) identified 15 controlled studies evaluating the impact of prophylactic surgeries including a bilateral risk-reducing mastectomy on women with *BRCA1* or *BRCA2* variants.<sup>5,</sup> In a meta-analysis of 6 studies with 2555 *BRCA1* or *BRCA2* variant carriers, compared with controls who did not receive a risk-reducing mastectomy, there was a significantly lower risk of subsequent breast cancer in women who had a bilateral risk-reducing mastectomy (relative risk [RR], 0.11; 95% confidence interval [CI], 0.04 to 0.32). However, in a meta-analysis of 2 studies in *BRCA1* or *BRCA2* variant carriers with no history of breast cancer, there was no significant effect on breast cancer-specific mortality (hazard ratio [HR], 0.29; 95% CI, 0.03 to 2.61) or on all-cause mortality (HR, 0.29; 95% CI, 0.03 to 2.61). Similarly, Ludwig et al (2016) identified 10 studies on the incidence of breast cancer after bilateral risk-reducing mastectomy in *BRCA1* or *BRCA2* carriers and found a significant reduction in breast cancer risk ranging from 89.5% to 100%.<sup>6,</sup> These reviewers did not conduct pooled analyses of studies on the impact of a risk-reducing mastectomy on mortality.

Honold and Camus (2018) extracted data from systematic reviews and primary studies to determine if risk-reducing mastectomy for women with *BRCA* genes is more effective than active surveillance (periodic clinical examination plus imaging tests) at preventing breast cancer.<sup>7,</sup> The authors analyzed data from 13 systematic reviews with a total of 50 studies. The results suggest with high certainty of evidence (based on GRADE system) that active surveillance is less effective at preventing breast cancer than risk-reducing mastectomy, with 254 per 1000 patients developing breast cancer with only active surveillance and 12 per 1000 with risk-reducing mastectomy (risk ratio, 0.05; 95% CI, 0.02 to 0.1). Mortality from any cause was also higher for active surveillance than for risk-reducing mastectomy (risk ratio, 0.12; 95% CI, 0.04 to 0.36). The authors also concluded with moderate evidence that up to 64% of women who received the surgery experienced adverse effects (eg, lower sensitivity, pain, infection, edema, contracture). In addition, they found low certainty of evidence that those who underwent risk-reducing mastectomy had a decrease in anxiety and depressive symptoms, did not regret having the surgery, and were satisfied with the cosmetic results. The results of this meta-analysis do not apply to individuals with low to moderate risk of breast cancer.

A Cochrane review by Carbine et al (2018) examined the impact of risk-reducing mastectomy on mortality and other health outcomes.<sup>8,</sup> Reviewers did not identify any RCTs. Sixty-one observational studies with some methodologic limitations were identified. The studies presented data on 15,077 individuals with a wide range of risk factors for breast cancer who underwent a risk-reducing mastectomy. Studies on the incidence of breast cancer and/or disease-specific mortality (n=21) reported reductions in both after a bilateral risk-reducing mastectomy, particularly for those with *BRCA1* or *BRCA2* variants.

# **Section Summary: Risk-Reducing Mastectomy**

Evidence from systematic reviews has found that risk-reducing mastectomy reduces the incidence of breast cancer in women at high-risk of breast cancer, especially those with *BRCA1*, *BRCA2*, and other pathogenic variants, and those with a formal high-risk familial risk assessment. In addition, 1 study reported that risk-reducing mastectomy could be associated with high satisfaction levels. Fewer studies have examined the impact of a risk-reducing mastectomy on overall or breast cancer-specific survival.

### CONTRALATERAL RISK-REDUCING MASTECTOMY

# **Clinical Context and Therapy Purpose**

The purpose of a contralateral risk-reducing mastectomy is to provide a treatment option that is an alternative to or an improvement on existing therapies in individuals with unilateral breast cancer who are not otherwise at high-risk.

The following PICO was used to select literature to inform this review.

# **Populations**

The relevant population of interest is individuals with unilateral breast cancer who are not otherwise at high-risk.

### Interventions

The therapy being considered is a contralateral risk-reducing mastectomy.

# **Comparators**

The following practice is currently being used to treat individuals with unilateral breast cancer who are not otherwise at high risk: active surveillance with clinical examination, imaging studies, and guideline-based treatment of primary breast cancer.

### **Outcomes**

The general outcomes of interest are OS, disease-specific survival, functional outcomes, and treatment-related morbidity.

# **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies;
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought;
- Studies with duplicative or overlapping populations were excluded.

### **REVIEW OF EVIDENCE**

# **Incidence of a Second Primary Breast Cancer**

The potential for a contralateral risk-reducing mastectomy to impact survival is related to its association with a reduced risk of subsequent primary breast cancer in the other breast (ie, contralateral breast cancer [CBC]). In general, according to data from the U.S. Surveillance, Epidemiology and End Results (SEER) database, annual rates of CBC were stable between 1975 and 1985, after which rates declined about 3% per year (95% CI, 2.7% to 3.5%). Beginning in 1990, the annual decline in CBC rates was only in individuals with estrogen receptor-positive cancer, with no decrease in individuals with estrogen receptor-negative cancer. The investigators suggested that the decrease in CBC rates after estrogen receptor-positive cancer might be attributed at least in part to the increased availability of adjuvant hormone therapies.

Studies were sought to assess the risk of CBC in women who met high-risk and average-risk criteria. Molina-Montes et al (2014) published a systematic review of studies on the risk of second primary breast cancer in women with and without *BRCA1* or *BRCA2* variants. <sup>10,</sup> Twenty studies were included (12 retrospective cohort studies, 2 prospective cohort studies, 6 case-control studies). Most studies included only individuals who had undergone genetic testing; it is likely that even those who tested negative had other risk factors that motivated testing. A meta-analysis found that the cumulative risk of second primary breast cancer at 5 years after the initial diagnosis was 14% (95% CI, 9% to 19%) in *BRCA1* or *BRCA2* variant carriers and 3% (95% CI, 2% to 5%) in noncarriers. The cumulative risk of a second primary cancer at 10 years after the initial diagnosis was 22% (95% CI, 18% to 27%) in *BRCA1* or *BRCA2* variants and 5% (95% CI, 3% to 7%) in noncarriers.

# **Survival After Contralateral Risk-Reducing Mastectomy**

As is the case for bilateral risk-reducing mastectomy, no RCTs evaluating the effect of contralateral risk-reducing mastectomy on health outcomes have been published. There are a number of observational studies, including some with large sample sizes, and systematic reviews of those observational studies. Observational studies have attempted to control for potential confounders, but not all relevant factors were measured, and the possibility of selection bias remains.

# **Systematic Reviews**

The previously summarized Cochrane review by Carbine et al (2018) also assessed various outcomes, including mortality and disease-free survival, among individuals who received a contralateral risk-reducing mastectomy. <sup>8,</sup> Twenty-six observational studies assessed outcomes in individuals who received contralateral risk-reducing mastectomy. While results showed a reduced incidence of CBC among those who received a contralateral risk-reducing mastectomy, results on disease-specific mortality were inconsistent. Seven of the included studies showed no survival advantage. One additional study showed an improvement in all-cause mortality associated with contralateral risk-reducing mastectomy; however, significance was lost after adjustment for bilateral risk-reducing salpingo-oophorectomy. The authors attributed the variability in mortality findings, in part, to selection bias, since younger, healthier individuals may be more likely to opt for contralateral risk-reducing mastectomy.

A systematic review and meta-analysis of studies on contralateral risk-reducing mastectomy were published by Fayanju et al (2014).<sup>11,</sup> The authors conducted a literature search through March 2012 and identified 17 observational studies that compared the incidence of CBC in individuals with unilateral disease who did and did not undergo a contralateral risk-reducing mastectomy. Fourteen of the 17 studies were included in various meta-analyses. In a meta-analysis of 4 studies, mortality from breast cancer was lower in the group that had a contralateral riskreducing mastectomy (RR, 0.69; 95% CI, 0.56 to 0.85). Moreover, in a meta-analysis of data from 6 studies, OS was significantly higher in patients who underwent a contralateral riskreducing mastectomy (n=10,666) than those who did not (n=145,490; RR, 1.09; 95% CI, 1.06 to 1.11). Reviewers also conducted a subgroup analysis by risk level. A meta-analysis of patients considered high-risk, which included BRCA variant carriers and/or those with a family history of breast cancer (4 studies, 616 undergoing contralateral risk-reducing mastectomy, 1318 not undergoing contralateral risk-reducing mastectomy) found that neither OS nor mortality from breast cancer differed significantly among individuals who had or did not have a contralateral risk-reducing mastectomy. The RR of breast cancer mortality with and without a contralateral risk-reducing mastectomy was 0.66 (95% CI, 0.27 to 1.64). For OS with and without a contralateral risk-reducing mastectomy, the RR was 1.09 (95% CI, 0.97 to 1.24). The absolute risk-reduction for metachronous breast cancer did not differ between individuals with and without a contralateral risk-reducing mastectomy when data from all 8 studies were analyzed (risk difference, -18.0%; 95% CI, -42.0% to 5.9%), but was significantly lower in those with a contralateral risk-reducing mastectomy in the 4 studies exclusively enrolling individuals at increased familial/genetic risk (risk difference, -24.0%; 95% CI, -35.6% to -12.4%). Commenting on the totality of findings, reviewers stated that the improvement in survival after a contralateral risk-reducing mastectomy in the general breast cancer population was likely not due to a decreased incidence of CBC, but rather was secondary to selection bias (eg, contralateral riskreducing mastectomy recipients may be otherwise healthier and have better access to health care).

#### **Observational Studies**

Studies in the Fayanju et al (2014) systematic review were published between 1997 and 2005. More recent large observational studies, described below, reported mixed results for OS and disease-specific survival.

An analysis of 17 years of SEER data from 245,418 women in California with unilateral breast cancer assessed secondary contralateral cancer incidence and mortality in women who had bilateral mastectomy or breast conserving therapy. 12, The study adjusted for numerous potential confounders, including demographic and socioeconomic characteristics, clinical characteristics and disease state, and year of diagnosis. Patient race/ethnicity was mostly White (65.1%), followed by Hispanic (15.9%) and Black (5.4%). After a median 7 years follow-up, the study found that when compared with breast conserving therapy that included radiotherapy, bilateral mastectomy was associated with a reduced risk of secondary breast cancer (HR, 0.11; 95% CI, 0.07 to 0.14) while unilateral mastectomy was associated with increased risk (HR, 1.07; 95% CI, 1.02 to 1.13). However, the study also found bilateral mastectomy was not associated with a significant reduction in breast cancer-related mortality relative to breast-conserving therapy (HR, 1.03; 95% CI, 0.96 to 1.11). Compared to White patients, Black (HR, 1.23; 95% CI, 1.13 to 1.35) and Filipina (HR, 1.30; 95% CI, 1.17 to 1.44) individuals had a higher risk of second contralateral breast cancer. Compared to White patients, Black patients had an increased risk of breast cancer death (HR, 1.21; 95% CI, 1.14 to 1.28) while individuals of all other races had a reduced risk of death.

Wong et al (2017) evaluated 496,488 individuals diagnosed with unilateral invasive breast disease. Within this cohort, 58.6% (n=295,860) underwent breast-conserving surgery, 33.4% (n=165,888) had a unilateral mastectomy, and 7% (n=34,740) had a contralateral risk-reducing mastectomy. The median age was 50 years in the contralateral risk-reducing mastectomy group and 60 years in the breast conservation group (p<.001). Patient race/ethnicity was mostly White (73.3%), followed by Black (9.5%), Hispanic (8.7%), and Asian/Pacific Islander (7.5%). Patients were followed for a median of 8.25 years. In an analysis adjusting for age and other factors including the stage of the disease, OS was significantly higher after breast conservation than after a contralateral risk-reducing mastectomy (HR, 1.08; 95% CI, 1.03 to 1.14). Similarly, breast cancer-specific survival was significantly higher in the breast conservation group than in the contralateral risk-reducing mastectomy group (HR, 1.08; 95% CI, 1.01 to 1.16).

An analysis of SEER data by Kruper et al (2014) suggested the association between contralateral risk-reducing mastectomy and reduced mortality identified in some data analyses could be attributed at least in part to the selection of a healthier cohort of women for contralateral risk-reducing mastectomy. In the case-control analysis including 28,015 contralateral risk-reducing mastectomy patients and 28,015 unilateral mastectomy patients in the SEER database, patients were matched by age group, race/ethnicity, extent of surgery, tumor grade, tumor classification, node classification, estrogen receptor status, and propensity score. The investigators were unable to match for *BRCA* or another genetic variant status. Patient race/ethnicity was mostly White (83%), followed by Hispanic (7%), Black (6%), and Asian/Pacific Islander (5%). When all matched patients were included, disease-specific survival and OS were significantly lower in

individuals who underwent unilateral mastectomy compared with contralateral risk-reducing mastectomy. For disease-specific survival, the HR was 0.83 (95% CI, 0.77 to 0.90); for OS, it was 0.77 (95% CI, 0.73 to 0.82). Presumably, a contralateral risk-reducing mastectomy would increase survival by lowering the risk of CBC. The authors conducted another analysis excluding individuals diagnosed with CBC; the remaining sample was still large (25,924 individuals with unilateral mastectomy, 26,299 individuals with contralateral risk-reducing mastectomy). In the analysis excluding those with CBC, disease-specific survival, and OS remained significantly lower in individuals who had unilateral versus contralateral risk-reducing mastectomy. For disease-specific survival, the HR was 0.87 (95% CI, 0.80 to 0.94); for OS, it was 0.76 (95% CI, 0.71 to 0.81). The investigators suggested that the survival benefits found in CBC patients were not due to prevention of CBC but to selection bias (eg, healthier individuals choosing CBC). A multivariate analysis showed that Black and Hispanic patients had increased risk of OS compared to White patients (HR, 1.63; 95% CI, 1.45 to 1.82 and HR, 1.21, 95% CI, 1.07 to 1.38, respectively). A limitation of the analysis was the inability to control for risk factors including gene variant status, family history, and a history of radiotherapy to the chest between ages 10 and 30 years.

Yao et al (2013) evaluated OS after contralateral risk-reducing mastectomy using data from the National Cancer Data Base. 1, The database collects information from 1450 Commission on Cancer-accredited cancer programs. The analysis included 219,983 individuals who had a mastectomy for unilateral breast cancer; 14,994 (7%) of these individuals underwent a contralateral risk-reducing mastectomy at the time of their mastectomy surgery. The investigators did not report risk factors such as known genetic variants. Patient race/ethnicity was mostly White (83.9%), followed by Black (8.9%), Hispanic (3.6%), and Asian/Pacific Islander (2.2%). The 5-year OS rate was 80%. In an analysis adjusting for confounding factors, the risk of death was significantly lower in patients who had a contralateral risk-reducing mastectomy than in those who did not. The adjusted HR for OS was 0.88 (95% CI, 0.83 to 0.93). The absolute risk of death over 5 years with contralateral risk-reducing mastectomy was 2.0% lower than without. In subgroup analyses, there was a survival benefit after contralateral risk-reducing mastectomy for individuals 18 to 49 years and 50 to 69 years but not for those 70 years or older. There was also a survival benefit for individuals with stage I and II tumors but not stage III tumors. Compared to White patients, Black patients had decreased survival (HR, 1.32; 95% CI, 1.27 to 1.37) while individuals of all other races had improved survival.

In a subsequent study, Pesce et al (2014) focused on a subgroup of patients who were young (<45 years old) with stage I or II breast cancer.<sup>15,</sup> A total of 4338 (29.7%) of 14,627 individuals in this subgroup had a contralateral risk-reducing mastectomy. Patient race/ethnicity was mostly White (76.5%), followed by Black (10.9%), Hispanic (7.6%), and Asian/Pacific Islander (4.4%). Median follow-up was 6.1 years. In a multivariate analysis controlling for potentially confounding factors, OS did not differ significantly between patients who underwent a unilateral mastectomy and those who also had a contralateral mastectomy (HR, 0.93; 95% CI, 0.79 to 1.09). Moreover, among individuals younger than 45 years with estrogen receptor-negative cancer, there was no significant improvement in OS in those who had a contralateral risk-reducing mastectomy or a unilateral mastectomy (HR, 1.13; 95% CI, 0.90 to 1.42). Compared to White patients, Black patients had decreased OS (HR, 1.48; 95% CI, 1.24 to 1.78). Among other races, OS was similar to White patients.

Yang et al (2021) conducted an analysis of SEER data from 1998 to 2016 of 5118 men with unilateral breast cancer who underwent contralateral risk-reducing mastectomy (n=209 [4.1%]).<sup>16,</sup> Patient race/ethnicity was mostly White (82.3%), followed by Black (12.4%), and other races (4.8%). In 1998, contralateral risk-reducing mastectomy was undertaken in 1.7% of men compared to 6.3% in 2016 (p<.0001). Compared to unilateral mastectomy, contralateral risk-reducing mastectomy improved OS (HR, 0.58; 95% CI, 0.37 to 0.89) but a survival benefit was not seen after propensity score-matching (HR, 0.83; 95% CI, 0.46 to 1.52). Contralateral risk-reducing mastectomy did not improve disease-specific survival compared to unilateral mastectomy.

### **Adverse Events**

There are risks and benefits associated with contralateral risk-reducing mastectomy. In particular, several analyses have found higher rates of surgical complications in individuals undergoing contralateral risk-reducing mastectomy (bilateral mastectomy) compared with those undergoing unilateral mastectomy. Besides morbidity associated with these complications, surgical complications may delay receiving adjuvant therapy.

Murphy et al (2021) published a systematic review and meta-analysis evaluating the complications associated with contralateral risk-reducing mastectomy. <sup>17,</sup> Fifteen cohort studies (14 retrospective; 1 prospective) were included (N=6583). Definitions of what constituted as a complication varied amongst the included studies. In patients who underwent unilateral plus contralateral prophylactic mastectomy, the diseased breast was significantly more susceptible to complications compared to the contralateral breast (RR, 1.24; p=.03). Studies that were stratified by reconstructive method reported that complication risk was significantly higher for unilateral plus contralateral prophylactic mastectomy compared to unilateral mastectomy alone in patients with no reconstruction (RR, 2.03; p=.0003), autologous reconstruction (RR, 1.32; p=.005), and prosthetic-based reconstruction (RR, 1.42; p=.003)

Schroeder et al (2020) conducted a population-based study of 12,959 women who underwent unilateral mastectomy or contralateral risk-reducing mastectomy using data from the New York Statewide Planning and Research Cooperative System.<sup>18,</sup> Of these, 1384 underwent a contralateral risk-reducing mastectomy and 11,575 underwent a unilateral mastectomy. After controlling for confounding factors (ie, race, ethnicity, year of operation, and type of insurance) and stratifying by breast reconstruction, no difference was found in the likelihood of complications or additional breast-related procedures needed between women who received contralateral risk-reducing mastectomy and those who received unilateral mastectomy (both without breast reconstruction). Addition of breast reconstruction was associated with significant increases in complications and breast-related procedures, both in women with unilateral mastectomy (odds ratio [OR], 3.6; p<.001 and OR, 13.7; p<.001, respectively) and in those with contralateral risk-reducing mastectomy (OR, 3.3; p<.001 and OR, 30.1; p<.001, respectively). Patients who underwent contralateral risk-reducing mastectomy were also significantly more likely to undergo breast reconstruction compared to those who underwent unilateral mastectomy (93.1% vs. 46.3%; p<.001).

Silva et al (2015) published a large multicenter study including 20,501 women with unilateral breast cancer from the American College of Surgeons National Surgery Quality Improvement Program database.<sup>19,</sup> A total of 13,268 (64.7%) women underwent a unilateral mastectomy, and

7233 (35.3%) had a bilateral mastectomy. The analysis did not report on high-risk factors such as BRCA variant status or family history. All women had breast reconstruction; a higher proportion of women who had a unilateral mastectomy (19.5%) than bilateral mastectomy (8.9%) had autologous reconstruction; the remainder had implant-based reconstruction. The authors conducted analyses controlling for confounding variables (ie, age, race, smoking, diabetes, chronic pulmonary disease, hypertension) and stratifying by type of implant. The rate of overall complications was significantly higher for women who had a bilateral mastectomy, regardless of reconstruction type. Among women with implant reconstructions, overall complication rates were 10.1% after a bilateral mastectomy and 8.8% after a unilateral mastectomy (adjusted OR, 1.20; 95% CI, 1.08 to 1.33). In women with autologous reconstructions, overall complication rates were 21.2% after a bilateral mastectomy and 14.7% after a unilateral mastectomy (adjusted OR, 1.60; 95% CI, 1.28 to 1.99). The most common complication was reoperation within 30 days, followed by surgical site complications. Transfusion rates were also significantly higher (p<.001) in women with bilateral mastectomies who had either type of reconstruction. The rates of medical complications were relatively lowapproximately 1% of women who had implant reconstructions and 3% of women who had autologous reconstructions experienced a medical complication (ie, pneumonia, renal insufficiency or failure, sepsis, urinary tract infection, venous thromboembolism)-and did not differ significantly between unilateral and bilateral mastectomies.

Several single-center studies have also reported significantly higher surgical complication rates after bilateral compared with unilateral mastectomy. For example, in a study by Miller et al (2013), which included 600 women with unilateral breast cancer, contralateral risk-reducing mastectomy remained associated with a significantly higher risk of any complication (OR, 1.53; 95% CI, 1.04 to 2.25) and a significantly higher risk of major complications (OR, 2.66; 95% CI, 1.37 to 5.19) compared with unilateral mastectomy. Moreover, in a study by Eck et al (2014), which assessed 352 women with unilateral breast cancer, 94 (27%) women had complications, 48 (14%) in the unilateral mastectomy group, and 46 (13%) in the bilateral mastectomy group. The difference between groups was not statistically significant (p=.11) but this study might have been underpowered. Eck et al (2014) found a significant delay in adjuvant therapy after surgical complications: women with complications waited longer before receiving adjuvant therapy than those without complications (49 days vs. 40 days, p<.001).

# **Section Summary: Contralateral Risk-Reducing Mastectomy**

Large observational studies have reported inconsistent findings on the survival benefit of contralateral risk-reducing mastectomy in women with unilateral breast cancer who do not otherwise meet high-risk criteria. Researchers have suggested that improvements in survival after contralateral risk-reducing mastectomy in the general breast cancer population found in some studies are due at least in part to selection bias. Moreover, there are risks of complications associated with both the surgical and reconstruction procedures.

### SUPPLEMENTAL INFORMATION

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

# **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

# **2016 Input**

In response to requests, input was received from 1 specialty society and 6 academic medical centers while this policy was under review in 2016. Input addressed the use of contralateral prophylactic (risk-reducing) mastectomy in women with unilateral breast cancer who are not otherwise at high-risk for developing breast cancer in the contralateral breast. The input was mixed. Clinicians offered suggestions for modifying high-risk criteria but there was no consensus on potential additional risk factors.

# **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

# **American College of Medical Genetics and Genomics**

In 2021, the American College of Medical Genetics and Genomics (ACMG) published a guideline on the management of individuals with *PALB2* variants, which recommends that risk-reducing mastectomy be considered as an option based on personal risk.<sup>22,</sup> In 2023, the ACMG published a guideline on the management of individuals with *CHEK2* variants, which also recommends that risk-reducing mastectomy be considered as an option based on personal risk.<sup>23,</sup>A 2025 ACMG guideline did not recommend risk-reducing mastectomy based on *ATM* variants.<sup>24,</sup>

# American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology

In 2020, the American Society for Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology published joint guidelines on management of hereditary breast cancer.<sup>25,</sup> The guideline discusses management of patients with breast cancer with germline mutations in breast cancer susceptibility genes (eg, *BRCA1/2, ATM, TP53*) and makes the following recommendations regarding risk-reducing mastectomy:

"Surgical management of the index malignancy (...contralateral risk-reducing mastectomy [CRRM]) in *BRCA1*/2 mutation carriers should be discussed, considering the increased risk of CBC [contralateral breast cancer] and possible increased risk of an ipsilateral new primary breast cancer compared with noncarriers (Type: formal consensus; Evidence quality: intermediate; Strength of recommendation: strong)."

"For women with breast cancer who have a *BRCA1/2* mutation and who have been treated or are being treated with unilateral mastectomy, CRRM should be offered. CRRM is associated with a decreased risk of CBC; there is insufficient evidence for improved survival."

"Decisions regarding risk-reducing mastectomy (bilateral or contralateral) are highly personal and must be individualized for every patient. Studies show that women who opt for prophylactic mastectomy report positive outcomes, including decreased concern about developing breast cancer. This benefit must be weighed against possible problems with implants or reconstructive therapy and potential adverse feelings related to body image, femininity, and sexuality. Most patients who opt for prophylactic mastectomy demonstrate satisfaction with their decision."

"For women with breast cancer who have a mutation in a moderate-penetrance breast cancer predisposition gene and who have been treated or are being treated with unilateral mastectomy, the decision regarding CRRM should not be based predominantly on mutation status. Additional factors that predict CBC such as age at diagnosis and family history should be considered, as they are in all cases. The impact of CRRM on decreasing risk of CBC is dependent on the risk of CBC for each individual gene. Data regarding the risk of CBC resulting from moderate-penetrance genes are limited (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate)."

The guideline also provides recommendations for assessing the risk of CBC and role of risk-reducing mastectomy in *BRCA1/2* mutation carriers (Evidence quality: low; Strength of recommendation: moderate) and in women with breast cancer who have a *BRCA1/2* mutation who have been treated or are being treated with unilateral mastectomy when considering contralateral risk-reducing mastectomy (Evidence quality: intermediate; Strength of recommendation: moderate). The quideline recommends consideration of the following:

- Age at diagnosis (the strongest predictor of future CBC)
- Family history of breast cancer
- Overall prognosis from this or other cancers (eg, ovarian)
- Ability of patient to undergo appropriate breast surveillance (magnetic resonance imaging [MRI])
- Comorbidities
- Life expectancy.

# **American Society of Breast Surgeons**

In 2016, a consensus statement from the American Society of Breast Surgeons made the following recommendations on contralateral risk-reducing mastectomy<sup>26,</sup>:

"CPM [contralateral prophylactic mastectomy] should be considered for those at significant risk of CBC [contralateral breast cancer]

- Documented BRCA1/2 carrier
- Strong family history, but patient has not undergone genetic testing
- History of mantle chest radiation before age 30 years.

CPM can be considered for those at lower risk of CBC

- Gene carrier of... CHEK-2, PALB2, p.53, CDH1
- Strong family history, patient BRCA negative, no known BRCA family member.

CPM may be considered for other reasons

- To limit contralateral breast surveillance (dense breasts, failed surveillance, recall fatigue)
- To improve reconstructed breast symmetry

• To manage risk aversion ... [or] extreme anxiety." (note: anxiety may be better managed through psychological support strategies.)

# CPM should be discouraged

- Average-risk women with unilateral breast cancer
- Women with advanced index cancer
- Women at high risk for surgical complications (e.g.,...comorbidities, obesity, smoker, diabetes)
- BRCA negative with a family of BRCA-positive carriers
- Male breast cancer, including BRCA carriers.

# **National Cancer Institute**

In 2025 , the National Cancer Institute updated its fact sheet on risk-reducing surgery for breast cancer. The fact sheet stated individuals may consider bilateral risk-reducing mastectomy if they are known to have inherited a harmful mutation that increases their risk of developing breast cancer. The Institute states that individuals who are at high risk of breast cancer but have not inherited a harmful mutation, should talk to their doctors about the potential advantages and disadvantages of a risk-reducing mastectomy. These individuals include those who have radiation therapy to the chest (including the breasts) prior to the age of 30 , as well as those who have pleomorphic lobular carcinoma in situ (PLCIS) together with a strong family history of breast cancer.

Considering contralateral risk-reducing mastectomy, the Institute stated that some individuals who have been diagnosed with cancer in one breast, especially those who are known to be at very high risk, may think about having the contralateral breast, removed; however, it is noted that physicians frequently advise against contralateral preventive mastectomy because these patients have a very low chance of getting breast cancer again, especially if they had adjuvant chemotherapy or hormone therapy during their treatment. Additionally, a contralateral mastectomy may raise the risk of complications and cause delays in treatment for the diagnosed cancer. Furthermore, there is currently insufficient evidence to suggest that contralateral prophylactic mastectomy lowers mortality.

# **National Comprehensive Cancer Network**

The National Comprehensive Cancer Network (NCCN) has made recommendations relevant to this evidence review.

For breast cancer risk-reduction (v.2.2025), the NCCN recommends: "Risk-reducing mastectomy should generally be considered only in those with a pathogenic/likely pathogenic genetic variant in high-penetrance breast cancer susceptibility genes, compelling family history, or those who received chest wall radiation before 30 years of age." "Risk estimation is a complex and individualized process; the NCCN Panel does not recommend a specific risk cutoff for decision making regarding risk reducing mastectomy. Individualizing management is important."<sup>28</sup>,

For invasive breast cancer (v.4.2025 ) the NCCN has discouraged contralateral risk-reducing mastectomy, except for certain high-risk situations (noted in the risk-reduction guideline previously discussed).  $^{29}$ , The guidelines state:

"....risk reduction mastectomy of a breast contralateral to a known unilateral breast cancer treated with mastectomy or breast-conserving therapy is discouraged by the Panel."

As part of a genetic/familial high-risk assessment for breast, ovarian, pancreatic, and prostate cancer (v.1.2026), the NCCN recommends that the option of risk-reduction mastectomy be discussed in women with *BRCA*-related breast and/or ovarian syndrome, Li-Fraumeni syndrome, and Cowden syndrome or PTEN hamartoma tumor syndrome. <sup>30,</sup> In addition, the NCCN guidelines recommend that risk-reducing mastectomy be considered for discussion in women with certain genetic variants *CDH1*, *PALB2*, *STK11*, and based on family history in women with other genetic variants including *ATM*, *NF1*, *CHEK2*, *RAD51D*, and *RAD51C*.

# **Society of Surgical Oncology**

In 2025, the Society of Surgical Oncology updated its position statement on risk-reducing mastectomy.<sup>31,</sup> The position statement concluded the following about risk-reducing mastectomy:

- "BRRM [bilateral risk-reducing mastectomy] may be considered for individuals who have a
  PV [pathogenic variant] in a high-risk breast cancer gene (i.e. BRCA1, BRCA2, TP53), or in
  certain moderate-risk genes (CDH1, PALB2, PTEN, or STK11); for individuals who have a
  strong family history; and in those with prior chest or breast radiation therapy prior to age
  30 years.
- There is insufficient evidence to support BRRM for PVs in *ATM, CHEK2, NF1, BARD1, RAD51C, or RAD51D*, however other risk factors such as a strong family may influence management.
- BRRM is not recommended for patients with ADH [atypical ductal hyperplasia], ALH
  [atypical lobular hyperplasia], LCIS [lobular carcinoma in situ], or other high-risk lesions
  of the breast. In the absence of other significant risk factors, BRRM is likely to reduce risk
  but not improve survival in these patients. Risk-reducing medications are the preferred
  risk-reduction strategy for patients with a personal history of ADH, ALH, or LCIS, if
  eligible."

In 2024, the Society of Surgical Oncology recommended that contralateral mastectomy in patients with unilateral breast cancer can be considered in:<sup>32,</sup>

 "Patients who have a high risk of contralateral breast cancer due to a germline mutation, prior chest irradiation, or strong family history."

They also recommended that contralateral mastectomy is contraindicated in patients who have increased risk of surgical complications or where longer anesthesia time may be detrimental. Contralateral mastectomy was recommended to be discouraged for patients with metastatic disease, patients with oligometastatic disease when a unilateral mastectomy is being performed for curative intent, patients with locally advanced breast cancer or inflammatory breast cancer for whom the rapid delivery of adjuvant therapy may impact outcomes, patients whose main reason for choosing contralateral mastectomy is improving survival or decreasing risk of recurrence of their index cancer, or patients with a significant competing risk of mortality secondary to their breast cancer, other malignancies, or comorbidities.

#### **U.S. Preventive Services Task Force Recommendations**

No U.S. Preventive Services Task Force recommendations for prophylactic mastectomy have been identified.

# **Ongoing and Unpublished Clinical Trials**

A search of ClinicalTrials.gov in July 2025 did not identify any ongoing or unpublished trials that would likely influence this review.

### **CODING**

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.

CPT/HCPCS		
19303	Mastectomy, simple, complete	

REVISIONS		
10-28-2011	Policy added to the bcbsks.com web site.	
07-13-2012	Description section updated.	
	In the Policy section:	
	• In Item #2, replaced "p" with "TP" to read "Presence of a TP53 or PTEN mutation"	
	(Note—this was a clarification. No policy intent change.) Rationale section updated.	
	,	
11 20 2012	Reference section updated.	
11-29-2013	Updated Description section.	
	<ul> <li>In Policy section:         <ul> <li>In Item A, removed "or moderately increased risk" to read "unilateral or bilateral prophylactic mastectomy may be considered medically necessary in patients at high risk of breast cancer with one of the following:"</li> <li>Removed Item A, #2</li> <li>Removed Item A, #7-#18</li> </ul> </li> <li>Added new #6 to Item A, "Li-Fraumeni syndrome or Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome or a first-degree relative with one of these syndromes."</li> <li>Added Item B, "Prophylactic mastectomy is considered experimental / investigational in women who do not meet high risk criteria."</li> <li>Updated Rationale section.</li> </ul>	
	In Coding section:	
	<ul> <li>Added ICD-10 Diagnosis codes. (Effective October 1, 2014)</li> </ul>	
	Updated Reference section.	
06-23-2015	Updated Description section.	
	In Policy section:	
	<ul> <li>In Item A 1, removed "Presence of a" and added "or" to read "A known BRCA1 or BRCA2 mutation, OR"</li> </ul>	
	In Item A 2, removed "radiation therapy" and added "radiotherapy" and "or" to read "Received radiotherapy to the chest between the ages of 10 and 30 years, OR"	
	■ In Item A 3, added "or" to read "Presence of lobular carcinoma in situ, OR"	

REVISIONS	
	In Item A 4, added "or" to read "Extensive mammographic abnormalities (i.e.,
	calcifications), OR
	• In Item A 5, removed "the Gail or Claus model (Characteristics of the Gail and Claus
	<ul> <li>models http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1#Section_66)," and added "developing", "models that are largely defined by family history", "or" to read "Lifetime risk of developing breast cancer of 20% or greater as identified by models that are largely defined by family history, OR"</li> <li>In Item A 6, added "or" to read "Li-Fraumeni syndrome or Cowden syndrome or Banayan-Riley-Ruvalcaba syndrome or a first-degree relative with one of these syndromes, OR"</li> <li>Added Item A 7, "Another gene mutation associated with increased risk (e.g., PTEN, TP53, CDH1, and STK11)."</li> <li>In Policy Guidelines, removed "Cancer risk assessment should include a complete family history and use of the Gail or Claus model to estimate the risk of cancer." and "should be discussed", and added "other than the operating surgeon and discussion of the", to read "It is strongly recommended that all candidates for prophylactic mastectomy undergo counseling regarding cancer risks from a health professional skilled in assess cancer risk other than the operating surgeon and discussion of the various treatment options, including increased surveillance or chemoprevention with</li> </ul>
	tamoxifen or raloxifene."
	Updated Rationale section.
10-01-2015	Updated References section.
10-01-2015	Policy published 05-25-2016. Retro-effective to 10-01-2015 with ICD-10 coding implementation.
	In Coding section:  • Added ICD-10 code: Z15.01.
05-25-2016	
03-23-2010	Updated Description section.  Updated Rationale section.
	Updated References section.
06-08-2016	In Revision section:
	<ul> <li>Removed "Updated Description, Updated Rationale, Updated References" sections from 10-01-2015 revision and created a 05-25-2016 revision.</li> </ul>
11-22-2016	<ul> <li>In Policy section:</li> <li>In Item B, removed "women" and added "individuals" to read, "Prophylactic mastectomy is considered experimental / investigational in women who do not meet high risk criteria."</li> </ul>
10-28-2017	Updated Description section.
	<ul> <li>In Policy section:</li> <li>In Item A 1, removed "mutation" and added "variant" to read, "A known BRCA1 or BRCA2 variant,"</li> <li>Removed Item A 4, "Extensive mammographic abnormalities (i.e., calcifications),</li> </ul>
	OR".
	<ul> <li>Removed Item A 6, "Li-Fraumeni syndrome or Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome or a first-degree relative with one of these syndromes, OR".</li> <li>In new Item A 5, removed "mutation" and added "variant", "(Li-Fraumeni syndrome)," and "(Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome)" to</li> </ul>
	read, "Another gene variant, associated with increased risk (e.g., <i>TI53</i> (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), <i>CDH1</i> , and <i>STK11</i> )."

REVISIONS	
	Updated Rationale section.
	Updated References section.
09-12-2018	Revised title from "Prophylactic Mastectomy."
	Updated Description section.
	In Policy section:
	<ul> <li>In Item A, removed "prophylactic" and added "risk-reducing" to read, "Unilateral or bilateral risk-reducing mastectomy may be considered medically necessary in patients at high risk of breast cancer with one of the following:"</li> <li>In Item B, removed "prophylactic" and added "risk-reducing" to read, "Risk-reducing mastectomy is considered experimental / investigational in individuals who do not meet high risk criteria."</li> <li>In Policy Guidelines, added new Item 4.</li> </ul>
	Updated Rationale section.
	In Coding section:  Removed ICD-9 codes.  Updated References section.
08-28-2019	Updated Description section.
00 20 2013	Updated Rationale section.
	Updated References section.
04-19-2021	Updated Description section.
01152021	Updated Rationale section.
	In the Coding section:
	Removed code 19304 (termed 12-31-20)
	Updated References section.
09-17-2021	Updated Rationale section.
05 17 2021	Updated Rationale section.
09-22-2022	Updated Description Section
	Updated Policy Section
	<ul> <li>Section A5 Added: "and PALBZ" to "Another gene variant associated with increased risk (e.g., TP53 [Li-Fraumeni syndrome], PTEN [Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome], CDH1, and STK11)."</li> <li>Section B Added: "for all other indications, including but not limited to contralateral risk-reducing mastectomy" and "with breast cancer" Reads: Risk-reducing mastectomy is considered experimental / investigational for all other indications, including but not limited to contralateral risk-reducing mastectomy in individuals with breast cancer who do not meet high risk criteria.</li> </ul>
	Updated Rationale Section
	<ul> <li>■ Removed ICD-10 codes: C50.011, C50.012, C50.111, C50.112, C50.211, C50.212, C50.311, C50.312, C50.411, C50.412, C50.511, C50.512, C50.611, C50.612, C50.811, C50.812, C50.911, C50.912, C50.021, C50.022, C50.121, C50.122, C50.129, C50.221, C50.222, C50.229, C50.321, C50.322, C50.329, C50.421, C50.422, C50.429, C50.521, C50.522, C50.529, C50.621, C50.622, C50.629, C50.821, C50.822, C50.829, C50.921, C50.922, C50.929, D05.11</li> <li>■ D05.12, D05.81, D05.82, D05.91, D05.92, Z85.3</li> <li>■ Added ICD-10 D05.00</li> <li>Updated References Section</li> </ul>
09-12-2023	Updated Description Section
05 12 2025	Updated Rationale Section
	Updated Coding Section
<u> </u>	spania sound seems

REVISIONS	5
	<ul> <li>Removed ICD-10 Codes</li> </ul>
	Updated References Section
10-22-2024	Updated Description Section
	Updated Rationale Section
	Updated References Section
10-28-2025	Updated Description Section
	Updated Rationale Section
	Updated Reference Section

### **REFERENCES**

- 1. Yao K, Winchester DJ, Czechura T, et al. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. Dec 2013; 142(3): 465-76. PMID 24218052
- 2. Baskin AS, Wang T, Bredbeck BC, et al. Trends in Contralateral Prophylactic Mastectomy Utilization for Small Unilateral Breast Cancer. J Surg Res. Jun 2021; 262: 71-84. PMID 33548676
- 3. McCarthy AM, Guan Z, Welch M, et al. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. J Natl Cancer Inst. May 01 2020; 112(5): 489-497. PMID 31556450
- 4. Watt GP, John EM, Bandera EV, et al. Race, ethnicity and risk of second primary contralateral breast cancer in the United States. Int J Cancer. Jun 01 2021; 148(11): 2748-2758. PMID 33544892
- 5. Li X, You R, Wang X, et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Clin Cancer Res. Aug 01 2016; 22(15): 3971-81. PMID 26979395
- 6. Ludwig KK, Neuner J, Butler A, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. Oct 2016; 212(4): 660-669. PMID 27649974
- Honold F, Camus M. Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers. Medwave. Jul 09 2018; 18(4): e7161. PMID 30052622
- Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. Apr 05 2018; 4(4): CD002748. PMID 29620792
- 9. Nichols HB, Berrington de González A, Lacey JV, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. Apr 20 2011; 29(12): 1564-9. PMID 21402610
- 10. Molina-Montes E, Pérez-Nevot B, Pollán M, et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast. Dec 2014; 23(6): 721-42. PMID 25467311
- 11. Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. Dec 2014; 260(6): 1000-10. PMID 24950272
- 12. Kurian AW, Canchola AJ, Ma CS, et al. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data

- from California, 1998 through 2015. Cancer. Mar 01 2020; 126(5): 958-970. PMID 31750934
- 13. Wong SM, Freedman RA, Sagara Y, et al. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg. Mar 2017; 265(3): 581-589. PMID 28169929
- 14. Kruper L, Kauffmann RM, Smith DD, et al. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. Ann Surg Oncol. Oct 2014; 21(11): 3448-56. PMID 25047478
- 15. Pesce C, Liederbach E, Wang C, et al. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. Oct 2014; 21(10): 3231-9. PMID 25081341
- 16. Yang Y, Pan L, Shao Z. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016. Breast Cancer Res Treat. Dec 2021; 190(3): 503-515. PMID 34554371
- 17. Murphy AI, Asadourian PA, Mellia JA, et al. Complications Associated with Contralateral Prophylactic Mastectomy: A Systematic Review and Meta-Analysis. Plast Reconstr Surg. Oct 01 2022; 150: 61S-72S. PMID 35943952
- 18. Schroeder MC, Tien YY, Erdahl LM, et al. The relationship between contralateral prophylactic mastectomy and breast reconstruction, complications, breast-related procedures, and costs: A population-based study of health insurance data. Surgery. Nov 2020; 168(5): 859-867. PMID 32819721
- 19. Silva AK, Lapin B, Yao KA, et al. The Effect of Contralateral Prophylactic Mastectomy on Perioperative Complications in Women Undergoing Immediate Breast Reconstruction: A NSQIP Analysis. Ann Surg Oncol. Oct 2015; 22(11): 3474-80. PMID 26001862
- 20. Miller ME, Czechura T, Martz B, et al. Operative risks associated with contralateral prophylactic mastectomy: a single institution experience. Ann Surg Oncol. Dec 2013; 20(13): 4113-20. PMID 23868655
- 21. Eck DL, Perdikis G, Rawal B, et al. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol. Oct 2014; 21(10): 3297-303. PMID 25047470
- 22. Tischkowitz M, Balmaña J, Foulkes WD, et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Aug 2021; 23(8): 1416-1423. PMID 33976419
- 23. Hanson H, Astiazaran-Symonds E, Amendola LM, et al. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Oct 2023; 25(10): 100870. PMID 37490054
- 24. Pal T, Schon KR, Astiazaran-Symonds E, et al. Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. Jan 2025; 27(1): 101243. PMID 39636577
- 25. Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. Jun 20 2020; 38(18): 2080-2106. PMID 32243226

- 26. Boughey JC, Attai DJ, Chen SL, et al. Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. Ann Surg Oncol. Oct 2016; 23(10): 3100-5. PMID 27469117
- 27. National Cancer Institute. Fact Sheet: Surgery to Reduce the Risk of Breast Cancer. 2025; https://www.cancer.gov/types/breast/risk-reducing-surgery-fact-sheet. Accessed July 18, 2025.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 2.2025. https://www.nccn.org/professionals/physician\_gls/pdf/breast\_risk.pdf. Accessed July 18, 2025.
- 29. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2025. https://www.nccn.org/professionals/physician\_gls/pdf/breast.pdf. Accessed July 16, 2025.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 1.2026. https://www.nccn.org/professionals/physician\_gls/pdf/genetics\_screening.pdf. Accessed July 17, 2025.
- 31. Singh P, Agnese DM, Amin M, et al. Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks. Ann Surg Oncol. Feb 2025; 32(2): 899-911. PMID 39538100
- 32. Singh P, Agnese D, Amin M, et al. Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks. Ann Surg Oncol. Apr 2024; 31(4): 2212-2223. PMID 38261126

# **OTHER REFERENCES**

- 1. Blue Cross and Blue Shield of Kansas Obstetrics and Gynecology, July 2003, May 2011.
- 2. Blue Cross and Blue Shield of Kansas Surgery Liaison Committee, August 2003, March 2004, August 2018, May 2023.
- 3. Blue Cross and Blue Shield of Kansas Oncology Liaison Committee, February 2004, CB-May 2011, July 2023.
- 4. Blue Cross and Blue Shield of Kansas Medical Advisory Committee, April 2004.
- 5. Blue Cross and Blue Shield of Kansas Surgery Liaison Committee, Consent Ballot, May 2011, August 2011; August 2013; August 2014; August 2015.